NDA 211280 · Eli Lilly and CO
Reyvow
Lasmiditan Succinate · Oral
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Sep 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 11, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
7 Phase 3, 1 recruiting
FAERS reports
1,163
206 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2026.
REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.
Mechanism: Lasmiditan binds with high affinity to the 5-HT 1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT 1F receptor; however, the precise mechanism is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- REYVOW · LASMIDITAN SUCCINATE EQ 100MG BASE · TABLET, ORAL · Discontinued
- REYVOW · LASMIDITAN SUCCINATE EQ 200MG BASE · TABLET, ORAL · Discontinued
- REYVOW · LASMIDITAN SUCCINATE EQ 50MG BASE · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Lasmiditan" as an intervention, any sponsor and status, largest first.
- Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02605174 · 3,005 participants · Start May 2016 · Primary completion Jun 30, 2017
Drug: Lasmiditan 50 mg; Lasmiditan 100 mg and 2 more · For: Migraine With or Without Aura
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 95 sites in all
- Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02439320 · 2,231 participants · Start Apr 2015 · Primary completion Jul 2016
Drug: Lasmiditan 100 mg; Lasmiditan 200 mg and 1 more · For: Acute Migraine
Sites: Birmingham, Alabama; Chandler, Arizona; Fountain Hills, Arizona · 92 sites in all
- An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT02565186 · 2,171 participants · Start Oct 7, 2015 · Primary completion Aug 20, 2019
Drug: Lasmiditan · For: Migraine Disorders
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 196 sites in all
- A Study of Lasmiditan (LY573144) Over Four Migraine AttacksPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03670810 · 1,633 participants · Start Jun 24, 2019 · Primary completion Jun 12, 2020
Drug: Lasmiditan; Placebo · For: Migraine
Sites: Huntsville, Alabama; Phoenix, Arizona; La Jolla, California · 141 sites in all
- A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigrainePivotal-lookingTerminated
Eli Lilly and CompanyEli Lilly (LLY)
NCT04396236 · 847 participants · Start Jun 15, 2020 · Primary completion Nov 12, 2025
Drug: Lasmiditan; Placebo · For: Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 152 sites in all
- A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With MigrainePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03962738 · 846 participants · Start May 31, 2019 · Primary completion Jun 8, 2020
Drug: Lasmiditan; Placebo · For: Migraine
Sites: Matsuyama, Japan; Kasuga-shi, Japan; Ota-shi, Japan · 34 sites in all
- A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigrainePivotal-lookingTerminated
Eli Lilly and CompanyEli Lilly (LLY)
NCT04396574 · 558 participants · Start Jun 30, 2020 · Primary completion Dec 4, 2025
Drug: Lasmiditan · For: Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 134 sites in all
- Dose-ranging Study of Oral COL-144 in Acute Migraine TreatmentPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00883051 · 512 participants · Start Jul 2009 · Primary completion Feb 2010
Drug: Lasmiditan; Placebo · For: Migraine Disorders
Sites: Montegnée, Belgium; Hasselt, Belgium; Leuven, Belgium · 39 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness210
- drug ineffective137
- feeling abnormal118
- somnolence109
- migraine89
- nausea86
- sedation79
- fatigue68
- headache66
- paraesthesia58
- hallucination44
- hypoaesthesia31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 334 |
| 2021 | 398 |
| 2022 | 128 |
| 2023 | 83 |
| 2024 | 95 |
| 2025 | 75 |
| 2026 | 50 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Reyvow (Lasmiditan Succinate)
2024 spending
$9.8M
Beneficiaries
3,067
11,829 claims
Per beneficiary
$3,187
$91.20 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,486,858 |
| 2021 | $5,806,062 |
| 2022 | $8,278,681 |
| 2023 | $9,927,259 |
| 2024 | $9,773,975 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.
VanderPluym JH, Halker Singh RB, Urtecho M, et al. · JAMA 2021 · Meta-Analysis, Research Support, U.S. Gov't, P.H.S.
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
Puledda F, Younis S, Huessler EM, et al. · Cephalalgia 2023 · Systematic Review, Network Meta-Analysis
- Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP, Liang CS, Chang CM, et al. · JAMA Netw Open 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana W, Jansem P, Anukoolwittaya P, et al. · J Headache Pain 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.